AMEU.F Stock Overview
A structural heart company, engages in the designing, developing, and commercializing medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Anteris Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.07 |
| 52 Week High | AU$15.53 |
| 52 Week Low | AU$5.55 |
| Beta | 0.75 |
| 11 Month Change | -24.16% |
| 3 Month Change | -43.56% |
| 1 Year Change | -54.26% |
| 33 Year Change | -13.31% |
| 5 Year Change | 9,607.84% |
| Change since IPO | 8,567.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMEU.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.5% | 1.7% | 0.3% |
| 1Y | -54.3% | 21.4% | 31.1% |
Return vs Industry: AMEU.F underperformed the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: AMEU.F underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| AMEU.F volatility | |
|---|---|
| AMEU.F Average Weekly Movement | 14.4% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMEU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AMEU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Wayne Paterson | anteristech.com |
Anteris Technologies Ltd, a structural heart company, engages in the designing, developing, and commercializing medical devices. The company’s lead product candidate is DurAVR, a transcatheter heart valve (THV) for the treatment of aortic stenosis. It also offers ComASUR, a delivery system that provides controlled deployment and placement of the DurAVR THV with balloon-expandable delivery, which allow precise alignment of the heart’s native commissures to achieve ideal valve positioning; and ADAPT, a patented anti-calcification tissue technology.
Anteris Technologies Ltd Fundamentals Summary
| AMEU.F fundamental statistics | |
|---|---|
| Market cap | US$133.29m |
| Earnings (TTM) | -US$57.26m |
| Revenue (TTM) | US$2.53m |
52.6x
P/S Ratio-2.3x
P/E RatioIs AMEU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMEU.F income statement (TTM) | |
|---|---|
| Revenue | AU$3.89m |
| Cost of Revenue | AU$2.25m |
| Gross Profit | AU$1.63m |
| Other Expenses | AU$89.53m |
| Earnings | -AU$87.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.16 |
| Gross Margin | 42.02% |
| Net Profit Margin | -2,260.86% |
| Debt/Equity Ratio | 5.3% |
How did AMEU.F perform over the long term?
See historical performance and comparison